Drug Price Trends for SAXAGLIPTIN HCL

Average Pharmacy Cost for SAXAGLIPTIN HCL

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
SAXAGLIPTIN HCL 5 MG TABLET	00378-4706-93	5.86407	EACH	2025-03-19
SAXAGLIPTIN HCL 2.5 MG TABLET	68462-0726-30	4.76606	EACH	2025-03-19
SAXAGLIPTIN HCL 5 MG TABLET	00378-4706-77	5.86407	EACH	2025-03-19
SAXAGLIPTIN HCL 2.5 MG TABLET	00378-4705-77	4.76606	EACH	2025-03-19
SAXAGLIPTIN HCL 2.5 MG TABLET	68462-0726-90	4.76606	EACH	2025-03-19
SAXAGLIPTIN HCL 2.5 MG TABLET	00378-4705-93	4.76606	EACH	2025-03-19
SAXAGLIPTIN HCL 2.5 MG TABLET	65862-0825-30	4.76606	EACH	2025-03-19

Saxagliptin HCL Market Analysis and Price Projections

Overview of Saxagliptin HCL

Saxagliptin HCL, commonly known by its brand name Onglyza, is an oral anti-diabetic drug belonging to the dipeptidyl peptidase 4 (DPP-4) inhibitors class. It is primarily used to treat type 2 diabetes mellitus, often in conjunction with a healthy diet and regular exercise to control blood sugar levels and prevent severe complications of diabetes such as kidney damage and blindness[3][4].

Market Size and Growth

The global saxagliptin market has been experiencing steady growth driven by several key factors. Here are some critical points:

• Market Size: The saxagliptin market is projected to reach $255 million by 2027, growing at a Compound Annual Growth Rate (CAGR) of 4.17% during the forecast period from 2022 to 2027[4].
• Regional Dominance: North America accounted for the highest revenue share in 2021 and is expected to continue dominating the market due to the increasing elderly population and sedentary lifestyle in the region. However, the Asia-Pacific region is anticipated to have the fastest CAGR during the forecast period, driven by factors such as a growing population in countries like India and China, and increasing healthcare spending[4].

Market Drivers

Several factors are driving the growth of the saxagliptin market:

• Increasing Incidence of Diabetes: The rising prevalence of type 2 diabetes, fueled by changing lifestyles, reduced physical exercise, and high obesity rates, is a significant driver[3][4].
• Government Financing and Healthcare Spending: Increased government financing and spending on healthcare, particularly in emerging economies, are boosting the market[4].
• Innovative R&D Activities: Continuous research and development in diabetes therapeutics are expected to propel market growth[3][4].

Market Restraints

Despite the growth drivers, there are several challenges that could restrain the market:

• Regulatory Framework: A strict regulatory framework for diabetic drugs can hinder market growth[3].
• Adverse Effects: Saxagliptin can cause adverse effects such as upper respiratory tract infections, urinary tract infections, and headaches, which may deter some patients[3].
• Risk of Cardiovascular Events: There is a risk of cardiovascular events like stroke and heart attack associated with saxagliptin, which can also hamper market growth[4].

Market Segmentation

The saxagliptin market is segmented based on several criteria:

By Dosage

• The market is segmented into 2.5 mg and 5 mg tablets. The 5 mg segment is expected to grow with the fastest CAGR during the forecast period due to the increasing application of Onglyza 5 mg film-coated tablets[4].

By Distribution Channel

• The market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Online pharmacies held the largest market share in 2021, driven by the convenience and increased use during the COVID-19 pandemic. However, hospital pharmacies are expected to grow with the fastest CAGR as life returns to pre-pandemic normalcy[4].

By Geography

• The market is analyzed across North America, Europe, Asia-Pacific, and other regions. North America dominates the market, but the Asia-Pacific region is expected to grow at the fastest rate due to its growing population and increasing healthcare spending[4].

Price Projections

The prices of saxagliptin vary based on dosage and distribution channels:

• 2.5 mg Oral Tablet: The cost for a 30-tablet supply of saxagliptin 2.5 mg oral tablets is around $454, with a per-unit price ranging from $15.14 to $15.16[2].
• 5 mg Oral Tablet: Similarly, the cost for a 30-tablet supply of saxagliptin 5 mg oral tablets is also around $454, with a per-unit price in the same range as the 2.5 mg tablets[2].

Cost Considerations

• The prices mentioned are for cash-paying customers and do not include discounts available through insurance plans or patient assistance programs[2][5].

Competitive Landscape

Key players in the saxagliptin market include:

• Bristol-Myers Squibb Company
• AstraZeneca plc

These companies are involved in various strategies such as new product launches, expansions, agreements, and acquisitions to maintain their market share and drive growth[1][3].

Key Takeaways

• The global saxagliptin market is driven by the increasing incidence of type 2 diabetes and innovative R&D activities.
• North America currently dominates the market, but the Asia-Pacific region is expected to grow at the fastest rate.
• The 5 mg dosage segment is projected to grow with the fastest CAGR.
• Online pharmacies have seen significant growth due to the COVID-19 pandemic, but hospital pharmacies are expected to grow rapidly as normalcy returns.
• Adverse effects and a strict regulatory framework are key restraints to market growth.

FAQs

Q: What is saxagliptin used for?

A: Saxagliptin is used to treat type 2 diabetes mellitus, often in conjunction with a healthy diet and regular exercise.

Q: What are the common dosages of saxagliptin?

A: Saxagliptin is available in 2.5 mg and 5 mg oral tablets.

Q: Which region dominates the saxagliptin market?

A: North America currently dominates the saxagliptin market, but the Asia-Pacific region is expected to grow at the fastest rate.

Q: What are the main drivers of the saxagliptin market?

A: The main drivers include the increasing incidence of type 2 diabetes, growing risk factors such as changing lifestyle and obesity, and innovative R&D activities in diabetes therapeutics.

Q: What are some potential restraints to the saxagliptin market?

A: Potential restraints include a strict regulatory framework for diabetic drugs, adverse effects such as upper respiratory tract infections and cardiovascular events, and complexities in alternative therapies for diabetes.

Sources

1. Radiant Insights: Global Saxagliptin Market Insights, Forecast to 2025
2. Drugs.com: Saxagliptin Prices, Coupons, Copay Cards & Patient Assistance
3. Allied Market Research: Saxagliptin Market Size, Share and Trends | Forecast by 2019 - 2026
4. IndustryARC: Saxagliptin Market - Forecast(2024 - 2030)
5. Drugs.com: Metformin/saxagliptin Prices, Coupons, Copay Cards & Patient Assistance